Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its financial results for the third quarter ended September 30, 2026, and provided updates on its liver therapeutics pipeline.
Stocks · News reference
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19
Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ARK Genomic Revolution ETF Increases Position in Arcturus Therapeutics
The ARK Genomic Revolution ETF (ARKG) increased its holdings in Arcturus Therapeutics Holdings Inc. by purchasing 64,483 shares.
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
Arcturus Therapeutics has scheduled the release of its third-quarter 2026 financial results and a corporate update for November 5, 2026.
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
Arcturus Therapeutics (NASDAQ:ARCT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.